Document detail
ID

oai:pubmedcentral.nih.gov:1045...

Topic
Communication
Author
Chen, Ruiting Chen, Hejing Peng, Huaping Zheng, Yanjie Lin, Zhen Lin, Xinhua
Langue
en
Editor

MDPI

Category

Biosensors

Year

2023

listing date

11/30/2023

Keywords
× cancer biosensor dna
Metrics

Abstract

Drug resistance in cancer is associated with overexpression of the multidrug resistance (MDR1) gene, leading to the failure of cancer chemotherapy treatment.

Therefore, the establishment of an effective method for the detection of the MDR1 gene is extremely crucial in cancer clinical therapy.

Here, we report a novel DNA biosensor based on an aligned multi-walled carbon nanotube (MWCNT) array modified electrode with 3D nanostructure for the determination of the MDR1 gene.

The microstructure of the modified electrode was observed by an atomic force microscope (AFM), which demonstrated that the electrode interface was arranged in orderly needle-shaped protrusion arrays.

The electrochemical properties of the biosensor were characterized by cyclic voltammetry (CV), differential pulse voltammetry (DPV), and electrochemical impedance spectroscopy (EIS).

Chronocoulometry (CC) was used for the quantitative detection of the MDR1 gene.

Taking advantage of the good conductivity and large electrode area of the MWCNT arrays, this electrochemical DNA sensor achieved a dynamic range from 1.0 × 10(−12) M to 1.0 × 10(−8) M with a minimal detection limit of 6.4 × 10(−13) M.

In addition, this proposed DNA biosensor exhibited high sensitivity, selectivity, and stability, which may be useful for the trace analysis of the MDR1 gene in complex samples.

Chen, Ruiting,Chen, Hejing,Peng, Huaping,Zheng, Yanjie,Lin, Zhen,Lin, Xinhua, 2023, Multi-Walled Carbon Nanotube Array Modified Electrode with 3D Sensing Interface as Electrochemical DNA Biosensor for Multidrug-Resistant Gene Detection, MDPI

Document

Open Open

Share

Source

Articles recommended by ES/IODE AI

Batoclimab as induction and maintenance therapy in patients with myasthenia gravis: rationale and study design of a phase 3 clinical trial
gravis myasthenia study clinical phase baseline improvement mg-adl 340 week trial placebo period mg maintenance qw